吸烟与前列腺癌风险及前列腺癌死亡风险:一项汇总研究
该汇总研究纳入五个瑞典队列中351448名有吸烟信息的男性,采用Cox回归计算风险比。结果显示吸烟与任何前列腺癌风险较低相关(HR 0.89,95%CI 0.86-0.92),但与前列腺癌死亡风险较高相关(HR 1.10,95%CI 1.02-1.18)。吸烟合并肥胖进一步降低低危前列腺癌风险并增加前列腺癌死亡风险。
要点
- 吸烟与任何前列腺癌风险较低相关(HR 0.89,95%CI 0.86-0.92),低危前列腺癌中更明显(HR 0.74,95%CI 0.69-0.79)。
- 吸烟与前列腺癌死亡风险较高相关(全队列HR 1.10,95%CI 1.02-1.18;病例分析HR 1.20,95%CI 1.11-1.31)。
- 吸烟合并肥胖(BMI≥30 kg/m2)进一步降低低危前列腺癌风险(HR 0.40,95%CI 0.30-0.53)并增加前列腺癌死亡风险(HR 1.49,95%CI 1.21-1.84)。
核心结论
- 吸烟者在PSA时代前列腺癌风险较低,尤其低危前列腺癌,可能归因于吸烟者PSA检测率低。
- 吸烟者生存较差,尤其肥胖吸烟者,需进一步研究以阐明原因及吸烟干预对前列腺癌死亡的预防潜力。
研究设计与样本
- 汇总研究纳入五个瑞典队列中351448名有吸烟信息的男性。
- 采用Cox回归计算前列腺癌发病(n=24731)和死亡(n=4322)的风险比(HR)和置信区间(CI)。
主要发现
- 吸烟与任何前列腺癌风险较低相关(HR 0.89,95%CI 0.86-0.92),低危前列腺癌中更明显(HR 0.74,95%CI 0.69-0.79),且仅限于PSA时代诊断的前列腺癌病例。
- 吸烟与前列腺癌死亡风险较高相关(全队列HR 1.10,95%CI 1.02-1.18;病例分析校正临床特征后HR 1.20,95%CI 1.11-1.31),各病例组间一致(异质性p=0.8)。
- 吸烟强度及程度较轻的吸烟时长和戒烟支持吸烟状态的关联。
- 吸烟合并肥胖(BMI≥30 kg/m2)进一步降低低危前列腺癌风险(HR 0.40,95%CI 0.30-0.53,与从不吸烟且BMI<25 kg/m2者比较)并进一步增加前列腺癌死亡风险(HR 1.49,95%CI 1.21-1.84)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅部分男性有前列腺癌诊断前后吸烟习惯的信息。
- 吸烟者生存较差,尤其肥胖吸烟者,需进一步研究以阐明原因及吸烟干预对前列腺癌死亡的预防潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prospective and detailed investigations of smoking and prostate cancer (PCa) risk and death are lacking. OBJECTIVE: To investigate prediagnosis smoking habit (status, intensity, duration, and cessation) as a risk factor, on its own and combined with body mass index (BMI), for PCa incidence and death. DESIGN, SETTING, AND PARTICIPANTS: We included 351448 men with smoking information from five Swedish cohorts. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We used Cox regression to calculate hazard ratios (HRs) and confidence intervals (CIs) for PCa incidence (n = 24731) and death (n = 4322). RESULTS AND LIMITATIONS: Smoking was associated with a lower risk of any PCa (HR 0.89, 95% CI 0.86-0.92), which was most pronounced for low-risk PCa (HR 0.74, 95% CI 0.69-0.79) and was restricted to PCa cases diagnosed in the prostate-specific antigen (PSA) era. Smoking was associated with a higher risk of PCa death in the full cohort (HR 1.10, 95% CI 1.02-1.18) and in case-only analysis adjusted for clinical characteristics (HR 1.20, 95% CI 1.11-1.31), which was a consistent finding across case groups (p = 0.8 for heterogeneity). Associations by smoking intensity and, to lesser degree, smoking duration and cessation, supported the associations for smoking status. Smoking in combination with obesity (BMI ≥30 kg/m2) further decreased the risk of low-risk PCa incidence (HR 0.40, 95% CI 0.30-0.53 compared to never smokers with BMI <25 kg/m2) and further increased the risk of PCa death (HR 1.49, 95% CI 1.21-1.84). A limitation of the study is that only a subgroup of men had information on smoking habit around the time of their PCa diagnosis. CONCLUSIONS: The lower PCa risk for smokers in the PSA era, particularly for low-risk PCa, can probably be attributed to low uptake of PSA testing by smokers. Poor survival for smokers, particularly obese smokers, requires further study to clarify the underlying causes and the preventive potential of smoking intervention for PCa death. PATIENT SUMMARY: Smokers have a higher risk of dying from prostate cancer, which further increases with obesity.
引用
- Jochems SHJ, Fritz J, Häggström C, et al. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. 2022. PMID: 35523620. doi:10.1016/j.eururo.2022.03.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。